Skip to main content

RheumNow Podcast – Periodontitis in RA Relatives (5.10.19)

May 10, 2019 3:00 am

Dr. Jack Cush reviews the news and journal articles from the past week on

  1. Initiating Urate Lowering Therapy (ULT) in 75 #Gout patients was associated with a 48% gout flare rate (within 3 mos of ULT). Risk factors include CRP >30mg/L, no prophylaxis (NSAID, colchicine)
  2. Analysis of claims data compared hospitalized infection rates among 11,248 matched pairs of new initiators of abatacept or TNF inhibitors. Serious hosp infections were significantly lower in ABA vs infliximab (HR 0.63; 0.47-0.85), but similar to ETN & ADA
  3. Danish population study of 55,037 found 210 men (37.6% RF+) & 456 women (41% RF+) RA pts; In women, body fat%, waist size, & obesity was assoc. w/ higher risk of RA. (10% higher for each 5% body fat, 5% for each 5- cm in waist, & 50% higher for obese)   
  4. In first-degree relatives of RA patients, comparing ACPA pos and neg FDR finds all moderate to severe periodontitis was significantly more prevalent in ACPA+ FDR (91%) compared to ACPA neg FDR (40%). From the Journal of Clinical Periodontology   
  5. Claims comparison of venous thromboembolic events (VTE) in treated RA pts finds a nonsignificant, but numerically higher rate of VTE in TOFA vs TNFi pts (0.60/100PY vs 0.34/100PY) (1.12/100PY vs 0.92/100PY), respectively. HR 1.33 (95% CI 0.78–2.24). 
  6. Cohort study finds 6/420 (1.4%) of SLE patients had steroid induced pancreatitis is - half of them died. Lit review finds 451 lupus pancreatitis with majority developing pancreatitis w/in 3 days of medium-to-high dose steroids (mortality = 37.5%). 
  7. Pilot Study Targets Insulin Resistence in Fibromyalgia  
  8. Calcineurin Inhibitors in Anti-Synthetase Dermatomyositis ILD 


The author has received compensation as an advisor or consultant on this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.